GOGavin Ovsak

Gavin Ovsak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gavin Ovsak has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Pablo Cata

    Department of Anesthesiology and Perioperative Medicine, MD Anderson Cancer Center, Houston, Texas

    2 shared publications
  • Adebukola Owolabi

    Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    1 shared publication
  • Alexander Wetzig

    Department of Orthopedic Surgery, University of Texas McGovern Medical School, Lyndon B. Johnson General Hospital, Houston, TX, USA

    1 shared publication
  • Andrzej P. Kwater

    Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    1 shared publication
  • Anvinh Nguyen

    Department of Anesthesiology, Baylor College of Medicine, Harris Health Ben Taub Hospitals, Houston, Texas, USA

    1 shared publication
  • Ashley Wetzig

    Department of Anesthesiology, Baylor College of Medicine, Harris Health Ben Taub Hospitals, Houston, Texas, USA

    1 shared publication

Latest Publications

  • Perioperative peripheral nerve blocks for elective below-knee amputations and phantom limb syndrome: an exploratory multicenter retrospective cohort study

    by Eric Hoang Nguyen, Kevin Hoffman, Sunny Gotewal, Ashley Wetzig, Alexander Wetzig, Andrzej Kwater, Adebukola Owolabi, Cassius Mensah, Gavin Ovsak, Anvinh Nguyen, et al.

    Background: Phantom limb syndrome (PLS) is a common complication following below-knee amputations (BKA) causing painful and/or nonpainful sensations in the absent limb. Peripheral nerve blocks (PNBs) are used for perioperative analgesia, but their association with PLS risk remains unclear. This study sought to evaluate potential associations regarding PLS incidence after BKA with and without PNBs. Methods: This retrospective cohort study was conducted using Epic Cosmos data from 2016 to 2025. Adults undergoing elective BKA were identified using Current Procedural Terminology codes 27880-27889 and categorized by PNBs versus none. The primary outcome was PLS diagnosis within 12 months of surgery using International Classification of Diseases, 10th Revision, Clinical Modification codes (G54.6, G54.7). Relative risks (RRs) were estimated using Mantel-Haenszel stratification adjusted for age, sex, and race only, with subgroup analysis by comorbidity burden. Secondary outcomes included length of stay (LOS). Results: Among 38 433 patients, 7430 (19.3%) received perioperative PNBs and 31 003 (80.7%) did not. PLS diagnosis coding occurred in 18.8% of the PNB group versus 15.1% of the non-block group (absolute difference 3.7%). Analysis adjusted for age, sex, and race only did not change the association (Mantel-Haenszel RR 1.24, 95% CI 1.20 to 1.28). PNBs were associated with a shorter LOS. All estimates should be considered exploratory associations. Conclusions: In this multicenter electronic health record-based cohort, exploratory analysis showed that perioperative PNB use was associated with increased rates of documented PLS coding across subgroups. However, the overall RR increase is modest. The observed association may reflect residual confounding by indication and differential surveillance rather than a causal effect. PNBs still remain appropriate for improving acute pain and reducing LOS. Prospective studies are needed to clarify causality and inform prevention strategies.

  • Enhanced recovery after surgery in minimally invasive hysterectomy for uterine cancer: identifying predictors of same-day discharge

    by Morgan Bou Zerdan, Mark F. Munsell, Gavin G. Ovsak, Jeffrey A. How, Roni Nitecki Wilke, Jolyn S. Taylor, Javier Lasala, Gabriel E. Mena, Pamela T. Soliman, Larissa A. Meyer, et al.

  • Postoperative shivering after intraoperative methadone administration: a retrospective cohort study

    by Eduardo Nunez-Rodriguez, Guanqing Chen, Gavin Ovsak, Jose Soliz, Evan D. Kharasch, Juan P. Cata

  • Open Access

    Sugammadex Versus Neostigmine in Return to Intended Oncological Therapy After Gastrointestinal Cancer Surgery: A Retrospective Study

    by Nicolas A. Cortes-Mejia, Juan J. Guerra-Londono, Tarikul Islam, Heather A. Lillemoe, Gavin Ovsak, Lei Feng, Juan P. Cata

    Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery. Methods: Adults (≥18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions. Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups. Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.